MA50488B1 - Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique - Google Patents

Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Info

Publication number
MA50488B1
MA50488B1 MA50488A MA50488A MA50488B1 MA 50488 B1 MA50488 B1 MA 50488B1 MA 50488 A MA50488 A MA 50488A MA 50488 A MA50488 A MA 50488A MA 50488 B1 MA50488 B1 MA 50488B1
Authority
MA
Morocco
Prior art keywords
anticholinergic
corticosteroid
dry powder
adrenergic
powder formulation
Prior art date
Application number
MA50488A
Other languages
English (en)
Other versions
MA50488A (fr
Inventor
Claudio Cafiero
Leonardo Ortenzi
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50488(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA50488A publication Critical patent/MA50488A/fr
Publication of MA50488B1 publication Critical patent/MA50488B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne une formulation de poudre sèche pour inhalation comprenant une combinaison d'un anticholinergique, d'un agoniste des récepteurs bêta2-adrénergiques à longue durée d'action et d'un corticostéroïde, et son procédé de préparation.
MA50488A 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique MA50488B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16

Publications (2)

Publication Number Publication Date
MA50488A MA50488A (fr) 2021-05-19
MA50488B1 true MA50488B1 (fr) 2021-09-30

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
MA43256A MA43256B1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50488A MA50488B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA43256A MA43256B1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA50487A MA50487B1 (fr) 2015-11-16 2016-11-14 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Country Status (36)

Country Link
US (4) US10086004B2 (fr)
EP (3) EP3377108B1 (fr)
JP (1) JP6963548B2 (fr)
KR (1) KR20180082443A (fr)
CN (1) CN108289962B (fr)
AR (1) AR106688A1 (fr)
AU (1) AU2016356858B2 (fr)
CA (1) CA3005290A1 (fr)
CL (1) CL2018001298A1 (fr)
CO (1) CO2018005141A2 (fr)
CY (3) CY1123042T1 (fr)
DK (3) DK3377108T3 (fr)
EA (1) EA037716B1 (fr)
ES (3) ES2895687T3 (fr)
GE (1) GEP20207157B (fr)
HR (3) HRP20211598T1 (fr)
HU (3) HUE056260T2 (fr)
IL (1) IL259329B (fr)
LT (3) LT3377108T (fr)
MA (3) MA43256B1 (fr)
MD (3) MD3628331T2 (fr)
ME (1) ME03778B (fr)
MX (1) MX2018005977A (fr)
MY (1) MY186229A (fr)
PE (1) PE20181488A1 (fr)
PH (1) PH12018501022A1 (fr)
PL (3) PL3628331T3 (fr)
PT (3) PT3628331T (fr)
RS (3) RS62506B1 (fr)
SA (1) SA518391570B1 (fr)
SG (2) SG10201912093YA (fr)
SI (3) SI3628331T1 (fr)
TW (1) TWI731891B (fr)
UA (1) UA125019C2 (fr)
WO (1) WO2017085004A1 (fr)
ZA (1) ZA201803168B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741427C1 (ru) * 2017-05-11 2021-01-26 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
MA48621A (fr) 2017-05-11 2021-04-28 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3947338A4 (fr) * 2019-03-27 2023-01-04 Kemin Industries, Inc. Procédés de préparation de carboxylates métalliques dans une réaction monotope
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (fr) * 2020-01-15 2021-07-22 四川海思科制药有限公司 Composition pharmaceutique de produit à inhaler pour aérosol contenant de l'indacatérol et procédé de préparation de celle-ci
WO2022045995A1 (fr) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de compositions de poudre sèche pour inhalation
US20220304894A1 (en) * 2021-03-24 2022-09-29 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DK1386630T3 (da) 2002-07-31 2006-09-11 Chiesi Farma Spa Pulverinhalator
WO2011076843A2 (fr) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Polythérapie pour bronchopneumopathie chronique obstructive (copd)
SI2928889T1 (en) * 2012-12-06 2018-05-31 Chiesi Farmaceutici S.P.A. COMPOUNDS WITH ACTIVITY OF ANTAGONIST OF MUSCARIN RECEPTORS AND BETA2 AGENTIST ADRENERGY RECEPTORS
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GEP20186853B (en) * 2013-07-11 2018-05-25 Chiesi Farma Spa Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation

Also Published As

Publication number Publication date
JP6963548B2 (ja) 2021-11-10
UA125019C2 (uk) 2021-12-29
MX2018005977A (es) 2018-08-29
MD3377108T2 (ro) 2020-07-31
LT3628331T (lt) 2021-11-10
CL2018001298A1 (es) 2018-09-14
DK3628331T3 (da) 2021-09-27
EA201890966A1 (ru) 2018-11-30
PT3628331T (pt) 2021-10-20
EA037716B1 (ru) 2021-05-13
DK3620176T3 (da) 2021-09-20
EP3620176A1 (fr) 2020-03-11
CN108289962A (zh) 2018-07-17
MY186229A (en) 2021-06-30
HRP20200537T1 (hr) 2020-06-26
PL3628331T3 (pl) 2021-11-08
DK3377108T3 (da) 2020-04-20
PT3620176T (pt) 2021-09-28
IL259329B (en) 2020-10-29
MA50487A (fr) 2021-04-28
MA43256B1 (fr) 2020-05-29
HRP20211598T1 (hr) 2022-01-07
ES2895687T3 (es) 2022-02-22
SI3377108T1 (sl) 2020-05-29
PH12018501022B1 (en) 2018-12-17
CO2018005141A2 (es) 2018-09-28
HRP20211600T1 (hr) 2022-01-21
HUE049751T2 (hu) 2020-10-28
CY1123042T1 (el) 2021-10-29
EP3377108B1 (fr) 2020-02-19
GEP20207157B (en) 2020-10-12
SG11201804050QA (en) 2018-06-28
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
ZA201803168B (en) 2019-07-31
JP2019501876A (ja) 2019-01-24
EP3620176B1 (fr) 2021-08-11
EP3628331A1 (fr) 2020-04-01
EP3377108A1 (fr) 2018-09-26
PH12018501022A1 (en) 2018-12-17
ME03778B (fr) 2021-04-20
RS62404B1 (sr) 2021-10-29
RS62506B1 (sr) 2021-11-30
US20210177866A1 (en) 2021-06-17
TW201722404A (zh) 2017-07-01
US10086004B2 (en) 2018-10-02
MA50488A (fr) 2021-05-19
ES2891073T3 (es) 2022-01-26
EP3628331B1 (fr) 2021-08-11
IL259329A (en) 2018-07-31
US10772896B2 (en) 2020-09-15
HUE056441T2 (hu) 2022-02-28
PL3377108T3 (pl) 2020-09-07
TWI731891B (zh) 2021-07-01
US20200368252A1 (en) 2020-11-26
AR106688A1 (es) 2018-02-07
AU2016356858B2 (en) 2021-06-24
CY1124475T1 (el) 2022-07-22
RS60171B1 (sr) 2020-05-29
HUE056260T2 (hu) 2022-02-28
KR20180082443A (ko) 2018-07-18
US20180360849A1 (en) 2018-12-20
SA518391570B1 (ar) 2022-03-27
BR112018009807A2 (pt) 2018-11-06
WO2017085004A1 (fr) 2017-05-26
ES2783855T3 (es) 2020-09-18
PL3620176T3 (pl) 2021-11-22
US20170136035A1 (en) 2017-05-18
SI3628331T1 (sl) 2021-11-30
CA3005290A1 (fr) 2017-05-26
CY1124490T1 (el) 2022-07-22
SI3620176T1 (sl) 2021-11-30
PE20181488A1 (es) 2018-09-18
AU2016356858A1 (en) 2018-05-31
PT3377108T (pt) 2020-04-08
US11628175B2 (en) 2023-04-18
CN108289962B (zh) 2021-09-14
MD3628331T2 (ro) 2021-12-31
LT3377108T (lt) 2020-07-10
SG10201912093YA (en) 2020-02-27
US10966991B2 (en) 2021-04-06
BR112018009807A8 (pt) 2019-02-26
MA43256A (fr) 2018-09-26
MA50487B1 (fr) 2021-09-30

Similar Documents

Publication Publication Date Title
MA50487B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201890967A1 (ru) Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
UA122348C2 (uk) Нові гетероциклічні антиестрогени
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
MA48620A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA48621A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA38782B1 (fr) Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
IN2014MU00386A (fr)
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll